指南与共识其他结缔组织病

系统性硬化症循证管理:EULAR/EUSTAR与BSR/BHPR指南对比解读

Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.
指南 / 共识 · Semin Arthritis Rheum · 2016-12-09

本文对比了更新的EULAR/EUSTAR与BSR/BHPR关于系统性硬化症(SSc)管理的推荐指南。EULAR/EUSTAR侧重药物治疗,BSR/BHPR扩展了非药物管理、心脏受累等域,两者多数一致。指南存在组合/二线治疗、间质性肺病治疗时机等照护缺口。

要点

  • EULAR/EUSTAR推荐以药物治疗为主,对检查和二线治疗指导有限。
  • BSR/BHPR补充了非药物措施、心脏受累、钙质沉着和肌肉骨骼表现的处理。
  • 间质性肺病治疗时机缺乏共识,部分并发症无循证推荐。

核心结论

  • EULAR/EUSTAR与BSR/BHPR指南可促进SSc最佳实践,但存在需进一步研究的照护缺口。

研究设计与样本

  • 本研究为指南对比分析,比较更新的EULAR/EUSTAR与BSR/BHPR系统性硬化症管理推荐。

主要发现

  • EULAR/EUSTAR指南聚焦SSc特征管理,纳入较新治疗模式数据并提及研究议程。
  • BSR/BHPR推荐与EULAR/EUSTAR的器官表现推荐相似,并扩展了一般措施、非药物治疗、心脏受累、钙质沉着和肌肉骨骼特征等域。
  • 两指南通常一致,但缺乏组合或二线治疗、算法建议及特定并发症的循证推荐。
  • 欧洲与北美专家因治疗可及性和适应证差异存在分歧。

关键数值与推荐

  • EULAR/EUSTAR推荐以药物治疗为主,较少涉及检查和ic非药物治疗。
  • BSR/BHPR扩展了多个治疗域,包括一般措施、非药物治疗、心脏受累、钙质沉着和肌肉骨骼特征。
  • 间质性肺病治疗时机缺乏共识,胃窦血管扩张症和勃起功能障碍无循证推荐。

临床怎么用

  • 临床可结合两份指南互补使用,以覆盖药物与非药物管理及器官并发症。
  • 对间质性肺病治疗时机、组合/二线治疗等缺口需个体化决策并关注未来更新。

局限性

  • 指南缺乏组合或二线治疗、算法建议及特定并发症的循证推荐。
  • 间质性肺病治疗时机无共识,欧洲与北美专家因治疗可及性和适应证存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Systemic sclerosis (SSc) is a rare heterogeneous connective tissue disease. Recommendations addressing the major issues in the management of SSc including screening and treatment of organ complications are needed. METHODS: The updated European League Against Rheumatism/European Scleroderma Trial and Research (EULAR/EUSTAR) and the British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines were compared and contrasted. RESULTS: The updated EULAR/EUSTAR guidelines focus specifically on the management of SSc features and include data on newer therapeutic modalities and mention a research agenda. These recommendations are pharmacologic, with few guidelines regarding investigations and non-pharmacologic management. Recommendations from BSR/BHPR are similar to the organ manifestations mentioned in the EULAR/EUSTAR recommendations, and expand on several domains of treatment, including general measures, non-pharmacologic treatment, cardiac involvement, calcinosis, and musculoskeletal features. The guidelines usually agree with one another. Limitations include the lack of guidance for combination or second-line therapy, algorithmic suggestions, the absence of evidence-based recommendations regarding the treatment of specific complications (i.e., gastric antral ectasia and erectile dysfunction). Consensus for when to treat interstitial lung disease in SSc is lacking. There are differences between Europe and North American experts due to access and indications for certain therapies. CONCLUSIONS: Care gaps in SSc have been demonstrated so the EULAR/EUSTAR and BSR/BHP guidelines can promote best practices. Certain complications warrant active investigation to further improve outcomes in SSc and future updates of these recommendations. Care gaps in SSc have been demonstrated so the EULAR/EUSTAR and BSR/BHP guidelines can promote best practices. Certain complications warrant active investigation to further improve outcomes in SSc.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. Semin Arthritis Rheum. 2016. PMID: 28088339. doi:10.1016/j.semarthrit.2016.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。